Clinical trial

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

NCT03495427

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention F-DCFPyL Injection Find medicine records · Find other trials using this name

DIAGNOSTIC_TEST · Unmapped registry intervention PSMA PET Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2, PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2019-12-18

PhasePHASE2 / PHASE3

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Recurrent Prostate Cancerunresolved

Interventions

F-DCFPyL InjectionDRUG

PSMA PETDIAGNOSTIC_TEST

Sponsors & collaborators

H. Lee Moffitt Cancer Center and Research Institutelead sponsor

Progenics Pharmaceuticals, Inc.collaborator

Mapped research locations

TampaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03495427 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.